Literature DB >> 11149495

Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.

L Dalle Carbonare1, M E Arlot, P M Chavassieux, J P Roux, N R Portero, P J Meunier.   

Abstract

Long-term treatment with glucocorticoids (GCs) leads to a rapid bone loss and to a greater risk of fractures. To evaluate the specific effects of this treatment on cancellous bone remodeling, structure, and microarchitecture, we compared 22 transiliac biopsy specimens taken in postmenopausal women (65 +/- 6 years) receiving GCs (> or = 7.5 mg/day, for at least 6 months) and 22 biopsy specimens taken in age-matched women with postmenopausal osteoporosis (PMOP), all untreated and having either at least one vertebral fracture or a T score < -2.5 SD. On these biopsy specimens, we measured static and dynamic parameters reflecting trabecular bone formation and resorption. Also, we performed the strut analysis and evaluated the trabecular bone pattern factor (TBPf), Euler number/tissue volume (E/TV), interconnectivity index (ICI), and marrow star volume (MaSV). Glucocorticoid-induced osteoporosis (GIOP), when compared with PMOP, was characterized by lower bone volume (BV/TV), trabecular thickness (Tb.Th), wall thickness (W.Th), osteoid thickness (O.Th), bone formation rate/bone surface (BFR/BS), adjusted mineral apposition rate/bone surface (Aj.AR/BS), and higher ICI and resorption parameters. After adjustment for BV/TV, the W.Th remained significantly lower in GIOP (p < 0.0001). The active formation period [FP(a+)] was not different. Patients with GIOP were divided into two groups: high cumulative dose GCs (HGCs; 23.7 +/- 9.7 g) and low cumulative dose GCs (LGCs; 2.7 +/- 1.2 g). HGC when compared with LGC was characterized by lower W.Th (p < 0.05), BV/TV (p < 0.001), Tb.Th (p < 0.05), trabecular number (Tb.N; p < 0.05), FP(a+)(p < 0.05), and nodes (p < 0.05), and higher E/TV (p < 0.05), ICI (p < 0.005), and TBPf (p < 0.05). When HGC was compared with PMOP, the results were similar except for the MaSV, which was significantly higher (p < 0.005). In summary, GIOP was characterized by lower formation and higher resorption than in PMOP, already present after LGC. With HGCs, these changes were associated with a more dramatic bone loss caused by a major loss of trabecular connectivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11149495     DOI: 10.1359/jbmr.2001.16.1.97

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  79 in total

1.  Osteocyte viability with glucocorticoid treatment: relation to histomorphometry.

Authors:  P N Sambrook; D R Hughes; A E Nelson; B G Robinson; R S Mason
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

2.  Bone density and cortical structure after pediatric renal transplantation.

Authors:  Anniek M Terpstra; Heidi J Kalkwarf; Justine Shults; Babette S Zemel; Rachel J Wetzsteon; Bethany J Foster; C Frederic Strife; Debbie L Foerster; Mary B Leonard
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

Review 3.  A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children.

Authors:  Karen E Hansen; Brian Kleker; Nasia Safdar; Christie M Bartels
Journal:  Semin Arthritis Rheum       Date:  2014-02-11       Impact factor: 5.532

4.  Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment.

Authors:  M Gelardi; F Barbara; I Covelli; M A Damiani; F Plantone; A Notarnicola; B Moretti; N Quaranta; G Ciprandi
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-08-01

5.  Implications of combined ovariectomy and glucocorticoid (dexamethasone) treatment on mineral, microarchitectural, biomechanical and matrix properties of rat bone.

Authors:  Parameswari Govindarajan; Thaqif Khassawna; Marian Kampschulte; Wolfgang Böcker; Britta Huerter; Lutz Dürselen; Miriam Faulenbach; Christian Heiss
Journal:  Int J Exp Pathol       Date:  2013-09-02       Impact factor: 1.925

Review 6.  Mechanisms of glucocorticoid action in bone.

Authors:  Ernesto Canalis
Journal:  Curr Osteoporos Rep       Date:  2005-09       Impact factor: 5.096

7.  Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats.

Authors:  L Dalle Carbonare; F Bertoldo; M T Valenti; S Zordan; S Sella; A Fassina; G Turco; G Realdi; V Lo Cascio; S Giannini
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

8.  Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.

Authors:  W Yao; W Dai; L Jiang; E Y-A Lay; Z Zhong; R O Ritchie; X Li; H Ke; N E Lane
Journal:  Osteoporos Int       Date:  2015-09-18       Impact factor: 4.507

9.  High bone marrow fat in patients with Cushing's syndrome and vertebral fractures.

Authors:  Francesco Ferraù; Salvatore Giovinazzo; Erika Messina; Agostino Tessitore; Sergio Vinci; Gherardo Mazziotti; Andrea Lania; Francesca Granata; Salvatore Cannavò
Journal:  Endocrine       Date:  2019-08-02       Impact factor: 3.633

Review 10.  Animal models for fracture treatment in osteoporosis.

Authors:  Marcus Egermann; J Goldhahn; E Schneider
Journal:  Osteoporos Int       Date:  2005-03-05       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.